Kintara Therapeutics, Inc. (KTRA)

NASDAQ: KTRA · IEX Real-Time Price · USD
0.184
+0.003 (1.66%)
At close: May 22, 2024, 4:00 PM
0.181
-0.003 (-1.68%)
After-hours: May 22, 2024, 7:59 PM EDT
1.66%
Market Cap 10.18M
Revenue (ttm) n/a
Net Income (ttm) -9.51M
Shares Out 55.30M
EPS (ttm) -4.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,304,029
Open 0.179
Previous Close 0.181
Day's Range 0.163 - 0.196
52-Week Range 0.081 - 5.600
Beta 0.41
Analysts Strong Buy
Price Target 14.00 (+7,508.7%)
Earnings Date May 14, 2024

About KTRA

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous m... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 2
Stock Exchange NASDAQ
Ticker Symbol KTRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for KTRA stock is "Strong Buy" and the 12-month stock price forecast is $14.0.

Price Target
$14.0
(7,508.70% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

SAN DIEGO , May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

8 days ago - PRNewsWire

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA

NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securiti...

6 weeks ago - PRNewsWire

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kintara Therap...

6 weeks ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA

MILWAUKEE , April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating Kintara (Nasdaq: KTRA) for possible breaches of fiduciary duty and other violations of law in its transaction with TuHURA. Click he...

7 weeks ago - PRNewsWire

KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kintara Therapeutics, Inc. (NASDAQ: KTRA) and TuHURA Biosciences, Inc. is fair to Kinta...

7 weeks ago - Business Wire

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 un...

7 weeks ago - PRNewsWire

Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

2 months ago - PRNewsWire

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

3 months ago - PRNewsWire

Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

- 15-patient Open Label Study to Confirm Planned Dose and Optimized Study Design Leading to a Phase 3 Clinical Trial in CMBC Patients - SAN DIEGO , Feb. 12, 2024 /PRNewswire/ -- Kintara Therapeutics, ...

3 months ago - PRNewsWire

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CORTMISTMOTSRPID
5 months ago - Benzinga

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AADIDRRX
5 months ago - Benzinga

Kintara Therapeutics Announces Review of Strategic Alternatives

- Ladenburg Thalmann Hired as Financial advisor - SAN DIEGO , Dec. 7, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused o...

5 months ago - PRNewsWire

Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

SAN DIEGO , Dec. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

6 months ago - PRNewsWire

Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CIDBVTMDPDCO
6 months ago - Benzinga

Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

6 months ago - PRNewsWire

Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study

- VAL-083 Did Not Perform Better Than Current Standards of Care - - Company Suspending Development of VAL-083, Shifting Focus to REM-001 Program and Other Strategic Opportunities - SAN DIEGO , Oct. 31...

7 months ago - PRNewsWire

Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference

SAN DIEGO , Oct. 11, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

8 months ago - PRNewsWire

Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference

SAN DIEGO , Oct. 2, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

8 months ago - PRNewsWire

Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

SAN DIEGO , Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, ...

8 months ago - PRNewsWire

Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update

SAN DIEGO , Sept. 18, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...

8 months ago - PRNewsWire

Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting

SAN DIEGO , Sept. 5, 2023 /PRNewswire/ --  Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...

9 months ago - PRNewsWire

Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023

SAN DIEGO , Aug. 17, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

9 months ago - PRNewsWire

Kintara Therapeutics to Present at the Emerging Growth Conference

SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

10 months ago - PRNewsWire

Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.

SAN DIEGO , July 19, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

11 months ago - PRNewsWire

Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001

SAN DIEGO , June 28, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

11 months ago - PRNewsWire